Ingredient news
Review Keeps Choline and Phospholipids in Focus for Neural Tube Risk
By Nutranexa News |
A 2026 review argues that choline deficiency may remain a meaningful neural-tube-defect risk even in folic-acid-fortified markets, keeping phospholipid-linked prenatal nutrition on buyers' radar.
What the Review Covered
The Birth Defects Research review examined animal and human evidence on choline and its derivatives, including betaine and phospholipids, in the occurrence and development of neural tube defects.
The authors positioned choline as a co-factor that should be considered alongside folate rather than after it.
Why It Matters
The review says emerging evidence suggests choline deficiency could still contribute to neural tube risk in populations where folic acid fortification is already established.
It also points to supplementation as a potentially useful risk-reduction tool, while acknowledging that more work is still needed.
Buyer Takeaway
For suppliers serving prenatal, pediatric, and women's-health channels, the paper adds weight to ongoing questions about choline form, dosage planning, and evidence hierarchy.
Ingredient files for prenatal concepts should keep composition, regulatory status, and claim discipline clearly separated from broader developmental research.